Evolus price target lowered to $19 from $20 at Mizuho

Mizuho lowered the firm’s price target on Evolus (EOLS) to $19 from $20 and keeps an Outperform rating on the shares. The firm reduced Jeuveau and Evolysse estimates citing the recent downdraft in consumer sentiment. It now sees increased likelihood of persistent inflationary pressure on demand for injectable facial aesthetic procedures. However, Evolus continues to have “compelling” long-term prospects, the analyst tells investors in a research note.